and Anti-Cancer Properties of (MGN-3), a modified xylose from rice bran,
in 5 Patients with Breast Cancer.
H. Ghoneum, Drew University of Medicine and Science, Dept. of Otolaryngology,
1621 E. 120th Street, Los Angeles, CA 90059
is a new biological response modifier (BRM). It is an extract of arabinoxylane
from rice bran that has been enzymatically modified to increase it's immunomodulatory
function. Five patients with breast cancer were given MGN-3 at 3g/d, then
NK cell activity was measured by 4-hr Cr-release assay using K562 tumor
cells as targets.
1 ) patients had low level of basal NK activity (13.5-34.9%) at effector:
to target (E:T) ratios of 12 and 100:1,that was significantly enhanced
by MGN-3 treatment (21.1-50.1%) at the same E:T ratios.
) The augmentation in NK activity was detected as early as 1-2 weeks post
treatment and was further increased with continuation of administering
patients who participated early in the study 6-8 mon.are in complete remission.
We conclude the high augmentory effect of MGN-3 on NK cells and the absence
of notable side effects make MGN-3 a promising BRM. In addition, immunotherapeutic
effect of MGN-3 in conjunction with chemotherapy may be useful in treatment
of cancer patients.
was offered by Daiwa Pharmaceutical co., Ltd. 1-16-19, Sangenjaya Setagaya,